Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03289481 · ClinicalTrials.gov registry record · Early Phase 1
Treatment of HFpEF With Nitrate Supplement
A Early Phase 1 study of Heart Failure With Normal Ejection Fraction, sponsored by MaineHealth.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT03289481 is a Early Phase 1 study of Heart Failure With Normal Ejection Fraction that has completed, run by MaineHealth. The registered enrollment target is 13 participants, below the 638-participant average among 10 other Heart Failure With Normal Ejection Fraction trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03289481, a Early Phase 1 study of Heart Failure With Normal Ejection Fraction, has completed, sponsored by MaineHealth.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this project is to determine if Neo40, a nitric oxide generating lozenge, when consumed twice daily by subjects with HFpEF, will increase exercise tolerance, decrease symptoms and improve quality of life for patients.
Conditions Studied
Interventions
- DRUG Placebo
- DIETARY_SUPPLEMENT Active lozenge
Study Locations (1)
Maine
- Penobscot Bay Medical Center - Rockport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2017-06-29 |
| Est. Completion | 2018-08-22 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03289481
The ClinicalTrials.gov registry entry for NCT03289481 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 638-participant average among 10 other Heart Failure With Normal Ejection Fraction trials with a reported enrollment target (98% lower). The listed sponsor is MaineHealth, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure With Normal Ejection Fraction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03289481 reports 1 study location spanning 1 distinct geographic area - top geographies include Maine.
Frequently Asked Questions
What is clinical trial NCT03289481 about?
NCT03289481 is a clinical study titled "Treatment of HFpEF With Nitrate Supplement". The objective of this project is to determine if Neo40, a nitric oxide generating lozenge, when consumed twice daily by subjects with HFpEF, will increase exercise tolerance, decrease symptoms and improve quality of life for patients.
What is the current status of trial NCT03289481?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 13 participants. The study started on 2017-06-29. Estimated completion is 2018-08-22.
What conditions does trial NCT03289481 study?
This clinical trial studies the following conditions: Heart Failure With Normal Ejection Fraction.
What interventions are being tested in trial NCT03289481?
The interventions under investigation include: Placebo (DRUG), Active lozenge (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03289481?
This trial is sponsored by MaineHealth, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03289481 being conducted?
This trial has 1 study location across Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure With Normal Ejection Fraction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise Intolerance in Heart Failure
RECRUITING
-
New Orleans Pulmonary Hypertension Biobank
RECRUITING
-
Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure
RECRUITING
-
Imaging Histone Deacetylase in the Heart
RECRUITING · NA
-
Ablation Versus Medical Management of Atrial Fibrillation in HFpEF
ACTIVE NOT RECRUITING · NA
-
Circulating RNAs in Acute Congestive Heart Failure
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.